Last reviewed · How we verify
Propionyl L-carnitine Hydrochloride
At a glance
| Generic name | Propionyl L-carnitine Hydrochloride |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study (PHASE3)
- Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis (PHASE3)
- PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses (PHASE1)
- A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese (PHASE1)
- Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements (NA)
- A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propionyl L-carnitine Hydrochloride CI brief — competitive landscape report
- Propionyl L-carnitine Hydrochloride updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI